Otsuka's Repinatrabit Shows Promising PKU Efficacy in Adolescents — Otsuka Pharmaceutical Co., Ltd.

Event summary

Otsuka presented open-label extension data for repinatrabit at the 2026 ACMG meeting, showing a -67% mean reduction in blood phenylalanine levels in adolescents with PKU.
The Phase 3 PheORD trial (NCT06971731) in adults is ongoing, with primary endpoint completion expected by late 2026.
Repinatrabit received orphan drug and rare pediatric disease designations from the FDA for PKU treatment.

The big picture

Otsuka's progress with repinatrabit underscores the growing focus on rare disease therapies, particularly those addressing metabolic disorders. The drug's potential to treat PKU across age groups and genotypes could expand its market reach significantly. With the Phase 3 trial underway, Otsuka is positioning itself as a key player in the PKU treatment landscape.

What we're watching

Clinical Validation: Whether the Phase 3 PheORD trial will confirm repinatrabit's efficacy across broader PKU patient populations.
Regulatory Pathway: The pace at which Otsuka can secure regulatory approvals for repinatrabit, leveraging its orphan drug designation.
Market Differentiation: How repinatrabit's novel mechanism of action will position it against existing PKU treatments like sapropterin.